Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbott\u2019s Once-A-Day Ivabradine Receives DCGI Approval for Heart Failure and Angina patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbott Announces Start of Trial to Evaluate the New Esprit\u2122 BTK Drug-Eluting Resorbable Scaffold","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca Pharma, Abbott Healthcare Terminate Distribution Agreements for Diabetes Drug in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbott Gets CDSCO Approval for Marketing of Estradiol, Dydrogesterone FDC","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbott Introduces Single-Dose Formulation of Carbetocin for Prevention of Postpartum Haemorrhage in India","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbott to Release Elecare\u00ae Amino Acid-Based Formulas to Help Meet Critical Patient Need","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Surmodics","pharmaFlowCategory":"D","amount":"$92.0 million","upfrontCash":"$25.0 million","newsHeadline":"Surmodics Receives FDA Approval for the SurVeil\u2122 Drug-Coated Balloon","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Mabxience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abbott Broadens Access to Cutting-edge Biosimilars in Key Emerging Markets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Abbott Laboratories

    Menu

    Abbott Laboratories

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Abbott Laboratories

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Abbott Broadens Access to Cutting-edge Biosimilars in Key Emerging Markets

              Details:

              Under the agreemeent, Abbott will commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East and Africa, and mAbxience will develop, manufacture and supply the biosimilar molecules.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Recipient: Mabxience

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement September 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Abbott Laboratories

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon

              Details:

              Under the agreement, Abbott has exclusive worldwide commercialization rights for the SurVeil (paclitaxel) drug-coated balloon (DCB) for which Surmodics received FDA approval.

              Lead Product(s): Paclitaxel

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: SurVeil

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Surmodics

              Deal Size: $92.0 million Upfront Cash: $25.0 million

              Deal Type: Agreement June 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Abbott Laboratories

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Abbott to Release Elecare® Amino Acid-Based Formulas to Help Meet Critical Patient Need

              Details:

              EleCare formulas are hypoallergenic and are used by infants and children who have severe food allergies or gastrointestinal (GI) disorders that require amino acid-based formulas.

              Lead Product(s): Amino Acid-Based Therapeutic

              Therapeutic Area: Nutrition and Weight Loss Product Name: Elecare

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Abbott Laboratories

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Abbott Introduces Single-Dose Formulation of Carbetocin for Prevention of Postpartum Haemorrhage in India

              Details:

              The novel, room-temperature-stable (RTS), single-dose formulation of Carbetocin will address prevailing challenges with existing protocols that require cold-chain storage and transportation.

              Lead Product(s): Carbetocin Acetate

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 31, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Abbott Laboratories

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Abbott Gets CDSCO Approval for Marketing of Estradiol, Dydrogesterone FDC

              Details:

              Estradiol, also spelled oestradiol, is an estrogen steroid hormone and the major female sex hormone. It is involved in the regulation of the estrous and menstrual female reproductive cycles.

              Lead Product(s): Estradiol,Dydrogesterone

              Therapeutic Area: Musculoskeletal Product Name: Femoston

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Abbott Laboratories

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AstraZeneca Pharma, Abbott Healthcare Terminate Distribution Agreements for Diabetes Drug in India

              Details:

              After termination of the agreement, AstraZeneca India will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapagliflozin and Saxagliptin in India under the brand names Forxiga, Xigduo and Qtern respectively.

              Lead Product(s): Dapagliflozin Propanediol Monohydrate,Metformin

              Therapeutic Area: Endocrinology Product Name: Xigduo

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: AstraZeneca

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Termination May 28, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Abbott Laboratories

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Abbott Announces Start of Trial to Evaluate the New Esprit™ BTK Drug-Eluting Resorbable Scaffold

              Details:

              This is the first Investigational Device Exemption (IDE) trial in the U.S. to evaluate a fully resorbable device to treat blocked arteries below the knees, or critical limb ischemia (CLI), in people battling advanced stages of peripheral artery disease (PAD).

              Lead Product(s): Everolimus

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: ESPRIT BTK

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 03, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Abbott Laboratories

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Abbott’s Once-A-Day Ivabradine Receives DCGI Approval for Heart Failure and Angina patients

              Details:

              Approval marks the first once-a-day formulation for Ivabradine in India, which will help increase adherence to therapy for chronic heart failure and chronic stable angina.

              Lead Product(s): Ivabradine Hydrochloride

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 02, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY